ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

Poster presentations: Basic Science 2020

P001 The novel DYRK1a inhibitor VRN024219 alleviates disease severity on the IBD mouse models by modulating T-cell differentiation

P002 Specific genome editing to model hypermethylation of the SP140 gene that associates to Crohn’s disease

P003 Metabolomics for improved patient stratification in inflammatory bowel disease: Characterisation of the ulcerative colitis metabolome

P004 PN-943, an oral α4β7 integrin antagonist, inhibits MAdCAM1-mediated proliferation and cytokine release from CD4+ T cells independent of trafficking

P005 Regulators of the guanylate cyclase pathway are potential novel markers of mucosal healing in IBD

P006 3D Multicellular intestine-on-a-chip model for disease modelling and drug discovery

P007 GC1qR driven oxidative phosphorylation is essential for intestinal goblet cell differentiation

P008 Whole-genome RNA sequencing in collagenous colitis: a subgroup analysis

P009 The innate cytokines IL-1α and TNF-α induce the expression of Oncostatin M and its type II receptor in human colonic subepithelial myofibroblasts

P010 Measurement of colonic mucosal content of biologics with the use of magnetic resonance imaging (MRI): A pilot study in patients with ulcerative colitis

P011 Dysbiosis and Goblet cells depletion triggers early intestinal barrier dysfunction that precedes gut inflammation in IL-10 deficient mice (IL-10−/−)

P012 α4β7 Receptor occupancy by vedolizumab at trough time-point occurs at the membranal level and is not associated with endoscopic healing in inflammatory bowel disease patients

P013 The JAK-3 and TYK-2 / STAT pathways are activated in moderate to severe ulcerative colitis

P014 Identification of Crohn’s disease immunopathotypes

P015 Tricellulin overexpression protects against elevated macromolecule uptake in DSS colitis mice

P016 Efficiency of evaluating the expression of Toll-like receptors 2, 4, 6 and proteins proteomic profiling as integral indicators for predicting the risk of early relapse of ulcerative colitis

P017 C86/CD16 macrophages accumulate in the mucosa of B3 patients and could mediate EMT in Crohn’s disease

P018 Per- and polyfluoroalkyl substances (PFAS) are significantly increased in patients with late-onset of ulcerative colitis

P019 Colonic mucosal kinase activity, cytokine and chemokine profiles in inflammatory bowel disease

P020 MAM, an anti-inflammatory protein derived from Faecalibacterium prausnitzii as a biomarker in Crohn’s disease?

P021 The influence of short-chain fatty acids produced by commensal bacteria on macrophage phenotype

P022 Impact of increasing disease symptom concordance between patients with inflammatory bowel disease and their physicians: insights from US, France, Germany, Italy, Spain and UK (5EU)

P023 Identification of regulated mechanistic pathways and genes to protect intestinal barrier injury by larazotide acetate in an IBD microenvironment

P024 Evaluation of the clinical course of patients diagnosed with primary sclerosing cholangitis: single centre study

P025 Evaluation of endoplasmic reticulum stress in intestinal mucosa from patients with Crohn’s disease

P026 The impact of different dietary factors in the etiopathogenesis of inflammatory bowel disease: a retrospective case–control study

P027 Repertoire analysis of memory T-cell receptors in Japanese patients with inflammatory bowel disease

P029 TRIM 21 protects against ulcerative colitis and colitic cancer via smad7 inhibition

P030 Dynamics of intestinal inflammation and microbial dysbiosis in pregnant women with IBD and their infants

P031 Therapeutic effect of OPS-2071 in a murine model of Crohn’s disease and in in vitro anti-inflammatory assays

P032 Increased endoplasmic reticulum stress-specific chaperones characterise CD fibrosis epithelium tissues and participate to in vitro induction of intestinal fibrobast differentiation

P033 Combination of vedolizumab with tacrolimus is more efficient in reducing intestinal inflammation than vedolizumab alone in the DSS-induced acute colitis mouse model

P034 GB004, a novel gut-targeted prolyl hydroxylase inhibitor, induces HIF-1α target genes and is efficacious in mouse colitis

P035 NUDT15 variance increases DNA-incorporated thiopurine metabolites and lymphocyte apoptosis in patients with inflammatory bowel disease

P036 A novel p53-mediated mouse model of inflammatory bowel disease-associated colorectal cancer

P037 Antagonism of chemokine receptor CCR9 synergises with anti-TNFα immunotherapy to reduce inflammation in the MDR1a^−/− mouse model of colitis

P038 A single-cell transcriptomics approach reveals high-resolution cellular signatures in Crohn’s disease

P039 Regional distribution of TCR Vδ1 and TCR Vδ2 cells in healthy and inflamed mucosa of inflammatory bowel disease

P040 Proteomic characterisation of serum extracellular vesicles in patients with inflammatory bowel diseases: a novel approach for biomarker discovery

P041 Melatonin controls microbiota in colitis through Toll-like receptor 4 signalling

P042 Patient perspective on the impact of complex perianal fistulas in Crohn’s disease on quality of life: introducing the concept of the patient survey conducted in Europe

P043 Small intestinal inflammation but not colitis drives pro-inflammatory nutritional antigen-specific T-cell response

P044 Milk derived exosomes has a therapeutic effect on experimental colitis

P045 Profiling of human circulating dendritic cells and monocytes subsets discriminates type and mucosal status in patients with inflammatory bowel disease

P046 Vitamin D decreases PDIA3 and prevents the enhanced migration of fibroblasts from stricturing Crohn’s disease

P047 Differences in extra cellular matrix remodelling in highly active Crohn’s disease and ulcerative colitis

P048 Mucosal macrophages express elevated levels of HDAC9 in inflamed and uninflamed mucosa of Crohn’s disease, but not ulcerative colitis

P049 A new preclinical rationale for first-line therapy of ulcerative colitis

P050 Analysis of 61 exclusive enteral nutrition formulas used for induction of remission in Crohn’s disease: new insights on dietary disease triggers

P051 Quantifying inflammation and fibrosis through a surgical histopathological score can differentiate ileal Crohn’s disease phenotypes and predict postoperative progressive disease

P052 Nuclear magnetic resonance metabolomic profiling of IBD patients under anti-TNF treatment. Are the pathways network deregulated?

P053 3-Oxo-C12:2, a quorum sensing molecule from the human gut, exerts anti-inflammatory effects through a bitter taste receptor

P054 The impact of intestinal stenosis on the expression of Crohn’s disease in young mice with genetic predisposition

P055 Effect of Mimosa caesalpiniifolia extract on DSS-induced colitis in Wistar rats

P056 Kefir (Lactobacillus kefiranofaciens) promotes autophagy and protects the intestinal barrier against DSS-induced colitis

P057 IL-17 regulates expression of chemotactic chemokines in human colonic subepithelial myofibroblasts

P058 The lived experience of family planning of female patients diagnosed with inflammatory bowel disease and their partners during key reproductive stages: a qualitative study

P059 Cytokine responsive transcriptional networks in inflammatory bowel disease

P060 The pharmacologic inhibition of store-operated calcium entry pathway in inflammatory bowel disease

P061 The molecular landscape of perianal fistula in Crohn’s disease: opportunities for new therapeutic approaches

P062 Dose-dependent differential effects of vedolizumab therapy on adhesion of regulatory and effector T cells

P063 B-cell receptor signalling in lymphoid tissues may be regulated by CEACAM1

P064 Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophage-dependent mechanism

P065 Metabolic utilisation of propanediol by adherent-invasive E. coli regulates intestinal tissue immunity

P066 Azathioprine linked with impaired intestinal epithelial regeneration in Crohn’s disease

P067 Proteins citrullination and Crohn’s disease: PAD4 but not PAD2 is a strong marker of ileal inflammation

P068 Erythrocyte and reticulocyte parameters in children with inflammatory bowel diseases

P069 CD73 promotes colitis-associated tumourigenesis in mice

P070 Machine learning approaches to identify IBD biomarkers from longitudinal microbiome data

P071 Studying the effects of the probiotic bifidobacteria on gut health and intestinal epithelial cells function

P072 Evaluation of dosing strategies of anti-TNFα monoclonal antibodies using pharmacokinetic modelling and simulation

P073 Compartmentalised human gut immunity: studies of innate and adaptive lymphocyte distribution in the epithelium, lamina propria and GALT of healthy gut mucosa by flow cytometry

P074 Histopathologic evaluation and lymphocyte subpopulations of the upper digestive tract of Crohn’s disease

P075 Muc5ac expression protects the colonic barrier in experimental colitis

P076 Role of gut microbiota in mediating the effects of thiopurines

P077 Metabonomic profiling distinguishes Crohn’s perianal fistulas and idiopathic idiopathic (cryptoglandular) perianal fistulas: possible clues to underlying pathogenesis?

P078 Efficiency of evaluating the expression of Toll-like receptors 2, 4, 6 and proteins proteomic profiling as integral indicators for predicting the risk of early relapse of ulcerative colitis

P079 High-dimensional mass cytometry after local MSC treatment in patients with refractory proctitis shows an effect on the myeloid compartment: preliminary data

P080 Therapeutical effect of urine-derived stem cells on DSS-induced chronic model of mice

P081 The structure of the proteomic profile and gut microbiota in patients with primary immunodeficiency, common variable immunodeficiency and inflammatory bowel disease

P082 Spicy food is a vital trigger for relapse in patient with inflammatory bowel disease

P083 Characterisation of T-cell receptor repertoire patterns of circulating a4b7 positive memory T cells in ulcerative colitis

P084 Cannabis use promotes lymphocyte responsiveness and modifies T-cell signalling in adolescent IBD patients

P085 Deep profiling of the circulating immune cell landscape in inflammatory bowel disease by mass cytometry

P086 Identification of constitutive modifications in plasma cells and B lymphocytes in patients with inflammatory bowel disease

P087 Biomarkers of elastin degradation differentiate between clinically inactive and active disease in ulcerative colitis patients

P088 TLR3 ameliorates colitis-associated colon tumourigenesis in mice

P089 Immune system cell differences between Crohn’s disease and ulcerative colitis patients in remission under anti TNF treatment

P090 Influence of high-fat diet on colitis and liver health in inflammatory bowel disease: a study using murine model of DSS-induced colitis

P091 Dietary triggers of colonic inflammation following treatment with exclusive enteral nutrition in children with Crohn’s disease

P092 Pathogenic B-cell response in ulcerative colitis that associates with treatment resistance and disease complications

P093 Crosstalk between Toll-like receptor 4 and enteric serotonergic pathways in a mouse model of dinitrobenzene sulfonic acid-induced colitis

P094 Differences in expression of PPARγ in small intestine vs. colon impact the effect of 5-aminosalicylates in inflammatory bowel disease

P095 PD-1 expressing T cells in patients with different types of colitis

P096 Specific plasma micro-RNA profiles for prediction of recurrence in Crohn’s disease in pre-surgery and established recurrence scenarios

P097 Depletion of delta-like ligand 4 (Dll4) contributes to the alteration of secretory progenitor differentiation in SAMP1/YitFc mice with Crohn’s disease-like ileitis

P098 Receptor-interacting protein 1 kinase inhibition therapeutically ameliorates experimental T-cell-dependent colitis in mice

P099 Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker in collagenous colitis

P100 CD161 levels are reduced in all subpopulations of T-cell colonic mucosal lymphocytes in inflammatory bowel disease

P101 Biomarkers of elastin degradation are associated with clinical and biochemically active disease in Crohn’s disease

P102 Host gene background and concentration influence the butyrate effect on modulating IECs proliferation

P103 The treatment effect of tonsil-derived mesenchymal stem cells (T-MSCs) via regulating programmed death-1/programmed death ligand-1 (PD-1/PD-L1) in ulcerative colitis

P104 Defective metabolism mediates NK cell dysfunction in inflammatory bowel disease (IBD)

P105 Glutathione S-transferase theta 1 protects against colitis through goblet cell differentiation via interleukin-22

P106 Depressive symptoms and anxiety and their screening in IBD patients: performance of the distress thermometer in Italian IBD patients

P107 The expression and regulation of Oncostatin M and its receptor in intestinal inflammation

P108 The importance of developing consensus-driven clinical data standards for Crohn’s disease to amplify data

P109 Construction of a suite of computable biological network models focused on inflammatory bowel disease

P110 Identification of the tryptophan metabolite 3-hydroxyanthranilic acid as a novel tool for the differentiation of Crohn’s disease phenotypes

P111 Elucidation of inflammatory infiltration of myenteric plexus in IBD

P112 Body composition and resting energy expenditure in IBD patients receiving biological therapy

P113 Serum adipokines as non-invasive biomarker in Crohn’s disease

P114 A screening tool for the early diagnosis of extraintestinal manifestations in inflammatory bowel disease: the EMAIL questionnaire